Myriad’s Prolaris team, focused on sales of prostate cancer molecular testing, was concerned about leveling sales and having limited success in achieving standard of care. We identified the barriers and market-validated the methods and assets needed to overcome those barriers. The results were accelerated sales per urologist, as well as an increase in total urologists adopting Prolaris as standard of care.